Combination of 131I-anti-endoglin monoclonal antibody and 5-fluorouracil may be a promising combined-modality radioimmunotherapy strategy for the treatment of hepatocellular carcinoma

Combination of 131I-anti-endoglin monoclonal antibody and 5-fluorouracil may be a promising combined-modality radioimmunotherapy strategy for the treatment of hepatocellular carcinoma

The present study aimed to investigate the therapeutic efficacy of combined radioimmunoconjugate 131I endoglin (ENG) and 5-fluorouracil (5-FU) in mouse model with hepatocellular carcinoma (HCC). HCC tumour SMMC7721-GFP xenograft-bearing mice were established and divided into four groups: control gro...

Full description

Bibliographic Details
Main Authors: Chongling Duan, Yanxiang Li, Weifei Yang, Chao Zhang
Format: Article
Language:English
Published: Taylor & Francis Group 2018-07-01
Series:Biotechnology & Biotechnological Equipment
Subjects:
131I
combination therapy
radioimmunotherapy
antiangiogenic therapy
endgolin
5-fluorouracil
hepatocellular carcinoma
Online Access:http://dx.doi.org/10.1080/13102818.2018.1475254

Internet

http://dx.doi.org/10.1080/13102818.2018.1475254

Similar Items